Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: A prospective cohort follow-up study

British Journal of Clinical Pharmacology

Volumn 48, Issue 5, 1999, Pages 756-760

  Lim, P O ^a   Jung, R T ^a   MacDonald, T M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Aldosterone renin ratio; Hypertension; Primary aldosteronism; Spironolactone

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; FLUDROCORTISONE; RENIN; SPIRONOLACTONE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; ORAL DRUG ADMINISTRATION; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALT LOADING; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; FEMALE; FLUDROCORTISONE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENIN; SPIRONOLACTONE;

EID: 0032708023     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00070.x     Document Type: Article

References (19)

1. 1 Gordon RD. Mineralocorticoid hypertension. Lancet 1994; 344: 240-243.
2. 2 Anis Anwar Y, White WB, Mansoor GA, et al. Hyperaldosteronism is a common cause of secondary hypertension missed by primary care physicians and associated with normokalaemia. Am J Hypertens 1998; 11 (4 part; 2): 199A (M001).
3. 3 Lim PO, Brennan G, Shiels P, et al. Unexpectedly high prevalence of primary aldosteronism in a hypertensive population in Dundee. J Endocrinol 1998; 156(Suppl): P22.
4. 4 Lim PO, Rodgers P, Cardale K, et al. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999; 353: 40.
5. 5 Gordon RD, Stowasser M, Klemm SA, et al. Primary aldosteronism and other forms of mineralocorticoid hypertension. In Textbook of Hypertension, ed. Swales J. Oxford: Blackwell Scientific, 1994: 865-892.
6. 6 Carey RM, Douglas JG, Schweikert JR, et al. The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone. Arch Intern Med 1972; 130: 849-854.
7. 7 Spark RF, Melby JC. Hypertension and low plasma renin activity: presumptive evidence for mineralocorticoid excess. Ann Intern Med 1971; 75: 831-836.
8. 8 Karlberg BE, Kagedal B, Tegler L, et al. Renin concentrations and effects of propranolol and spironolactone in patients with hypertension. Br Med J 1976; 1: 251-254.
9. 9 Solheim SB, Sundsfjord JA, Giezendanner L. The effect of spironolactone (Aldactone) and methyldopa in low and normal renin hypertension. Act Med Scand 1975; 197: 451-456.
10. 10 Adlin EV, Marks AD, Channick BJ. Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity. Arch Intern Med 1972; 130: 855-858.
11. 11 Ferguson RK, Turek DM, Rovner DR. Spironolactone and hydrochlorothiazide in normal-renin and low-renin essential hypertension. Clin Pharmacol Ther 1977; 21: 62-69.
12. 12 Sundsfjord JA, Odegaard AE. Renin levels and spironolactone treatment in general practice: similar blood pressure lowering effect of spironolactone in low and normal renin patients. Eur J Clin Invest 1977; 7: 389-392.
13. 13 Drayer JI, Kloppenborg PW, Festen J, et al. Intrapatient comparison of treatment with chlorthalidone, spironolactone and propranolol in normoreninemic essential hypertension. Am J Cardiol 1975; 36: 716-721.
14. 14 Henry M, Wehrlen M, Pelletier B, et al. Spironolactone versus nifedipine in essential hypertension. Am J Cardiol 1990; 65: 36K-38K.
15. 15 Lim PO, Brennan GM, Jung RT, et al. Diagnosing primary aldosteronism with frusemide stimulation test in hypertensive patients with raised aldosterone to renin ratio. Med Biochem 1999 in press.
16. 16 Helber A, Wambach G, Hummerich W, et al. Evidence for a subgroup of essential hypertensives with non-suppressible excretion of aldosterone during sodium loading. Klin Wochenschr 1980; 58: 439-447.
17. 17 Anonymous. Spironolactone: no longer for hypertension. Drug Ther Bull 1988; 26: 88.
18. 18 Takeda R, Yamazaki T, Ito Y, et al. Twenty-four year spironolactone therapy in an aged patient with aldosterone-producing adenoma. Acta Endocrinol 1992; 126: 186-190.
19. 19 McInnes GT. Diuretics. In Meyler's Side Effects of Drugs 13, ed. Dukes MNG. Amsterdam: Elsevier, 1996: 558-582.